Published in J Neurochem on May 26, 2007
Maladaptive striatal plasticity in L-DOPA-induced dyskinesia. Prog Brain Res (2010) 1.23
Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia. Proc Natl Acad Sci U S A (2010) 1.05
L-DOPA-induced dyskinesia is associated with regional increase of striatal dynorphin peptides as elucidated by imaging mass spectrometry. Mol Cell Proteomics (2011) 0.96
Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models. Neurobiol Dis (2014) 0.88
Proteomics in animal models of Alzheimer's and Parkinson's diseases. Ageing Res Rev (2008) 0.88
Serotonin hyperinnervation and upregulated 5-HT2A receptor expression and motor-stimulating function in nigrostriatal dopamine-deficient Pitx3 mutant mice. Brain Res (2012) 0.78
Transcriptional alterations under continuous or pulsatile dopaminergic treatment in dyskinetic rats. J Neural Transm (Vienna) (2010) 0.76
Tumor Necrosis Factor-Associated Protein 1 (TRAP1) is Released from the Mitochondria Following 6-hydroxydopamine Treatment. Exp Neurobiol (2014) 0.75
Anatomo-proteomic characterization of human basal ganglia: focus on striatum and globus pallidus. Mol Brain (2014) 0.75
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet (2007) 3.95
TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity. Proc Natl Acad Sci U S A (2013) 3.33
Comparing functional annotation analyses with Catmap. BMC Bioinformatics (2004) 2.92
Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse. Neuropharmacology (2007) 2.39
Generation of regionally specified neural progenitors and functional neurons from human embryonic stem cells under defined conditions. Cell Rep (2012) 2.31
Methods for the detection and analysis of protein-protein interactions. Proteomics (2007) 2.29
Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res (2007) 1.91
The protein expression of Streptococcus pyogenes is significantly influenced by human plasma. J Proteome Res (2005) 1.55
Signal transduction pathway profiling of individual tumor samples. BMC Bioinformatics (2005) 1.55
Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice. Curr Protoc Neurosci (2007) 1.46
Folding free energies of 5'-UTRs impact post-transcriptional regulation on a genomic scale in yeast. PLoS Comput Biol (2005) 1.46
Proteomic analysis and discovery using affinity proteomics and mass spectrometry. Mol Cell Proteomics (2011) 1.44
Detection of pancreatic cancer using antibody microarray-based serum protein profiling. Proteomics (2008) 1.38
Metabotropic glutamate receptor (mGluR5) antagonist MPEP attenuated cue- and schedule-induced reinstatement of nicotine self-administration behavior in rats. Neuropharmacology (2005) 1.34
Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res (2007) 1.28
Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia. J Neurochem (2006) 1.26
140 mouse brain proteins identified by Ca2+-calmodulin affinity chromatography and tandem mass spectrometry. J Proteome Res (2006) 1.21
VGLUT2 in dopamine neurons is required for psychostimulant-induced behavioral activation. Proc Natl Acad Sci U S A (2009) 1.21
Nanopipette delivery of individual molecules to cellular compartments for single-molecule fluorescence tracking. Biophys J (2007) 1.20
Assertive outreach teams in London: models of operation. Pan-London Assertive Outreach Study, part 1. Br J Psychiatry (2003) 1.18
Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J Neurochem (2006) 1.17
Rural to urban migration and changes in cardiovascular risk factors in Tanzania: a prospective cohort study. BMC Public Health (2010) 1.16
mGlu1 receptor blockade attenuates cue- and nicotine-induced reinstatement of extinguished nicotine self-administration behavior in rats. Neuropharmacology (2006) 1.15
The role of the NMDA receptor in alcohol relapse: a pharmacological mapping study using the alcohol deprivation effect. Neuropharmacology (2005) 1.15
The effects of acamprosate and neramexane on cue-induced reinstatement of ethanol-seeking behavior in rat. Neuropsychopharmacology (2005) 1.12
Large-scale proteomics analysis of human ovarian cancer for biomarkers. J Proteome Res (2007) 1.12
Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. J Neurochem (2007) 1.12
Caring for carers of people with stroke: developing a complex intervention following the Medical Research Council framework. Clin Rehabil (2005) 1.11
Binding of calcium ions and SNAP-25 to the hexa EF-hand protein secretagogin. Biochem J (2007) 1.09
Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease. Prog Neurobiol (2011) 1.09
Predictors of quality of life in ulcerative colitis: the importance of symptoms and illness representations. Inflamm Bowel Dis (2005) 1.08
Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia. Neurobiol Dis (2004) 1.07
Quantitative proteomics targeting classes of motif-containing peptides using immunoaffinity-based mass spectrometry. Mol Cell Proteomics (2012) 1.07
Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology (2002) 1.06
A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol Dis (2010) 1.04
Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine. Behav Pharmacol (2006) 1.04
Effects of NAAG peptidase inhibitor 2-PMPA in model chronic pain - relation to brain concentration. Neuropharmacology (2006) 1.03
Metabolomic and proteomic analysis of a clonal insulin-producing beta-cell line (INS-1 832/13). J Proteome Res (2007) 1.03
Effects of group I metabotropic glutamate receptor antagonists on the behavioral sensitization to motor effects of cocaine in rats. Psychopharmacology (Berl) (2006) 1.02
The antiproliferative effect of dietary fiber phenolic compounds ferulic acid and p-coumaric acid on the cell cycle of Caco-2 cells. Nutr Cancer (2011) 1.02
Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats. Eur J Pharmacol (2005) 1.01
Biomarker discovery: a proteomic approach for brain cancer profiling. Cancer Sci (2007) 1.01
Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease. Brain Res Bull (2006) 1.00
Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane. Pharmacol Biochem Behav (2006) 1.00
Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition. Behav Pharmacol (2009) 1.00
Protein expression changes in ovarian cancer during the transition from benign to malignant. J Proteome Res (2012) 1.00
Plasma lipid composition and risk of developing cardiovascular disease. PLoS One (2013) 0.99
Neuroprotective activity of selective mGlu1 and mGlu5 antagonists in vitro and in vivo. Eur J Pharmacol (2006) 0.99
Automated selected reaction monitoring software for accurate label-free protein quantification. J Proteome Res (2012) 0.99
Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia. Neurobiol Dis (2005) 0.98
Effects of nicotinic and NMDA receptor channel blockers on intravenous cocaine and nicotine self-administration in mice. Eur Neuropsychopharmacol (2005) 0.98
Diagnosis of type 2 diabetes at an older age: effect on mortality in men and women. Diabetes Care (2004) 0.98
Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. J Pharmacol Exp Ther (2009) 0.98
Characterization of the lipid droplet proteome of a clonal insulin-producing β-cell line (INS-1 832/13). J Proteome Res (2012) 0.97
Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease. Neurotox Res (2013) 0.96
Wavelet-based method for noise characterization and rejection in high-performance liquid chromatography coupled to mass spectrometry. Anal Chem (2008) 0.96
Comparison of the mGlu(5) receptor positive allosteric modulator ADX47273 and the mGlu(2/3) receptor agonist LY354740 in tests for antipsychotic-like activity. Eur J Pharmacol (2009) 0.96
NMDA receptor stimulation induces reversible fission of the neuronal endoplasmic reticulum. PLoS One (2009) 0.95
Effects of mGlu1 receptor blockade on working memory, time estimation, and impulsivity in rats. Psychopharmacology (Berl) (2007) 0.93
Multisite phosphorylation of adipocyte and hepatocyte phosphodiesterase 3B. Biochim Biophys Acta (2007) 0.93
Analysis of macular thickness in British population using optical coherence tomography (OCT): an emphasis on interocular symmetry. Curr Eye Res (2008) 0.93
The role of excitotoxicity in neurodegeneration. Folia Neuropathol (2005) 0.93
Effects of a positive allosteric modulator of mGluR5 ADX47273 on conditioned avoidance response and PCP-induced hyperlocomotion in the rat as models for schizophrenia. Pharmacol Biochem Behav (2009) 0.92
The anxiolytic and analgesic properties of fenobam, a potent mGlu5 receptor antagonist, in relation to the impairment of learning. Neuropharmacology (2009) 0.92
The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration. Behav Brain Res (2006) 0.92
Microarray analysis of gliomas reveals chromosomal position-associated gene expression patterns and identifies potential immunotherapy targets. J Neurooncol (2007) 0.92
Behavioral characterization of GLT1 (+/-) mice as a model of mild glutamatergic hyperfunction. Neurotox Res (2008) 0.92
Gene expression profiling in primary breast cancer distinguishes patients developing local recurrence after breast-conservation surgery, with or without postoperative radiotherapy. Breast Cancer Res (2008) 0.92
Automated methods for improved protein identification by peptide mass fingerprinting. Proteomics (2004) 0.91
Strategy for surveying the proteome using affinity proteomics and mass spectrometry. Proteomics (2009) 0.90
Automated reporting from gel-based proteomics experiments using the open source Proteios database application. Proteomics (2007) 0.90
Somatostatin effects on the proteome of the LNCaP cell-line. Int J Oncol (2007) 0.90
Tracking diffusion of GM1 gangliosides and zona pellucida binding molecules in sperm plasma membranes following cholesterol efflux. Dev Biol (2010) 0.89
Generic workflow for quality assessment of quantitative label-free LC-MS analysis. Proteomics (2011) 0.89
Analgesic effects of morphine and loperamide in the rat formalin test: interactions with NMDA receptor antagonists. Eur J Pharmacol (2005) 0.89
Effects of it takes two to talk--the hanen program for parents of preschool children with cerebral palsy: findings from an exploratory study. J Speech Lang Hear Res (2009) 0.89
c-Jun N-terminal kinase phosphorylation of MARCKSL1 determines actin stability and migration in neurons and in cancer cells. Mol Cell Biol (2012) 0.89
Antagonism of glutamatergic NMDA and mGluR5 receptors decreases consumption of food in baboon model of binge-eating disorder. Eur Neuropsychopharmacol (2008) 0.88
Mass spectrometry analysis of a protein kinase CK2beta subunit interactome isolated from mouse brain by affinity chromatography. J Proteome Res (2008) 0.88
Evaluation of brain pharmacokinetics of (+)MK-801 in relation to behaviour. Neurosci Lett (2011) 0.87
Differential proteomic analysis of HT29 Cl.16E and intestinal epithelial cells by LC ESI/QTOF mass spectrometry. J Proteomics (2009) 0.87
Behavioural and cellular effects of exogenous amyloid-β peptides in rodents. Behav Brain Res (2011) 0.87
Altered chaperone and protein turnover regulators expression in cultured skin fibroblasts from type 1 diabetes mellitus with nephropathy. J Proteome Res (2007) 0.86
N-methyl-D-aspartate and group I metabotropic glutamate receptors are involved in the expression of ethanol-induced sensitization in mice. Behav Pharmacol (2006) 0.86
A label-free nano-liquid chromatography-mass spectrometry approach for quantitative serum peptidomics in Crohn's disease patients. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 0.86
Dopamine release from serotonergic nerve fibers is reduced in L-DOPA-induced dyskinesia. J Neurochem (2011) 0.86
Aspirin users attending for NHS bowel cancer screening have less colorectal neoplasia: chemoprevention or false-positive faecal occult blood testing? Digestion (2012) 0.86